Hepatocellular carcinoma in Central, Eastern, and Southern Europe. What Future after the SHARP Trial?

• Authors: Roberto Iacovelli
• Languages of publication: EN
• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2009
• Volume: 4
• Issue: 1
• Pages: 138-139

Dates

published

1 - 3 - 2009

online

11 - 2 - 2009

Contributors

author

Roberto Iacovelli

• Department of Experimental Medicine, Oncology Unit B., “Sapienza” University of Rome, 00161, Rome, Italy

References

• [1] American Cancer Society: Cancer Facts and Figures 2007. Atlanta, Ga: American Cancer Society, 2007
• [2] International agency for Cancer Research, The GLOBOCAN 2002 database. Available at: http://www-dep.iarc.fr
• [3] Zhu A.X., Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma, Cancer, 2008, 112, 250–9 http://dx.doi.org/10.1002/cncr.23175[Crossref]
• [4] Shimoda K., Mori M., Shibuta K., Banner B.F., Barnard G.F., Vascular endothelial growth factor/vascular permeability factor mRNA expression in patients with chronic hepatitis C and hepatocellular carcinoma, Int. J. Oncol., 1999, 14, 353–359 [PubMed]
• [5] Poon R.T., Lau C., Pang R., Ng K.K., Yuen J., Tat Fan S., High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies, Ann. Surg. Oncol., 2007, 14, 1835–1845 http://dx.doi.org/10.1245/s10434-007-9366-z[Crossref]
• [6] Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., et al., Sorafenib in advanced hepatocellular carcinoma, N. Engl. J. Med., 2008, 359, 378–90 http://dx.doi.org/10.1056/NEJMoa0708857[Crossref]
• [7] http://www.clinicaltrial.gov/ct2/search

Identifiers

DOI

10.2478/s11536-008-0089-8